Clinical trial of TC-210 T CELLS in Patients with Advanced Mesothelin Expressing Cancer

Age
99 years or below
Gender
All
participants needed
25
Location
1
Clinical trial of TC-210 T CELLS in Patients with Advanced Mesothelin Expressing Cancer

Brief description of study

Your partner is participating in a research study which is looking to determine the safety and efficacy of the drug product, TC-210 T Cells. Your partner has received theTC-210 T Cells. You are being asked to provide information to the Sponsor and your partner’s study doctor, because your partner has reported that you became pregnant from him while he was enrolled in this study. To date, no information has been collected on pregnant women whose partners have been exposed to the TC-210 T Cells. There is a risk that the study medications may affect the development of the fetus if a woman is exposed to the study medications by transfer via semen leading to pregnancy.
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cancer
  • Age: 99 years or below
  • Gender: All


Updated on 04 Aug 2024. Study ID: 833254
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research